Jorge E. Cortes, MD | Authors

March 10, 2022

Jorge E. Cortes, MD and Hagop Kantarjian, MD share a summary on ponatinib in CML and ALL and exploration of potential future studies.

March 03, 2022

Experts review future implications such as using ponatinib in earlier lines of therapy and in patients with Ph-positive ALL.

March 03, 2022

Jorge E. Cortes, MD and Hagop Kantarjian, MD debate optimal dosing and discuss how they use ponatinib in patients with CML.

February 24, 2022

Hagop Kantarjian, MD responds to a review of dosing options in patients with CML treated with ponatinib.

February 24, 2022

Dr. Cortes reviews ponatinib dosing strategies based on patient profiles and mutational status.

February 17, 2022

Hematologic oncologists summarize the dose ranging study of ponatinib in patients with CML and discuss clinical implications of this work.

February 17, 2022

Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.

November 14, 2021

“I’ve done a lot of work [not only with] clinical trials, but also understanding the disease, the prognostic factors, and the management of adverse effects.”

June 06, 2017

This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.

June 01, 2016

Myelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including abnormalities in proliferation, differentiation, and apoptosis.